Introduction: Hyaluronic acid injections are becoming increasingly common among both the general public and the medical community, but they are not without risks. The occurrence of blindness, although rare, is a tragic event for both the patient and the practitioner. One of the treatments proposed in the literature is to inject hyaluronidase as close as possible to the site of ischemia, retrobulbarly. The aim of our study is to evaluate the effectiveness and potential benefits of retrobulbar hyaluronidase injections.
Materials And Methods: A literature review was conducted using the PubMed database. Only articles addressing retrobulbar hyaluronidase injections for the treatment of blindness following hyaluronic acid injections were included.
Results: We identified 12 case reports or series, comprising a total of 16 patients. Among these 16 patients, 3 regained their vision. Hyaluronidase was injected between 20minutes and 7days after the onset of the complication, with injected doses ranging from 3×150IU to 3×1500IU.
Discussion: Literature reveals only 3 cases of successful treatment out of the 16 reported injections. The time interval before retrobulbar injection, as well as the dose and the experience of the injecting practitioner, may influence the success rate of this treatment. Other treatments, such as intravascular hyaluronidase injections, remain to be explored.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anplas.2023.10.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrobulbar Hyaluronidase in Hyaluronic Acid-Induced Ocular Vascular Occlusion: Efficacy, Challenges, and Implications for Clinical Practice.
Aesthetic Plast Surg
October 2024
Intensive Therapy Unit, General Hospital of Castellon, Castellon, Spain.
Introduction: Ophthalmic vascular occlusion due to hyaluronic acid (OVOH) is a rare but devastating complication of cosmetic filler injections, often resulting in severe vision loss.
Materials: The methodology involved a systematic search across PubMed, NCBI, Google Scholar, and Cochrane to investigate factors influencing central retinal artery occlusion (CRAO) caused by fillers. Searches focused on "eye vascular anatomy," "ocular physiology in response to ischemia," "components AND hyaluronic acid AND inflammation," "recovery from blindness associated with fillers," "retrobulbar technique," and "hyaluronidase degradation AND fillers.
Retrobulbar Hyaluronidase Injection for Vascular Side Effects.
Aesthetic Plast Surg
October 2024
Division in Anatomy & Developmental Biology, Department of Oral Biology, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
Causes and management of sight threatening complications of dermal filler injections: A review.
Clin Exp Ophthalmol
April 2024
The Eye Institute Hawke's Bay, Hastings, New Zealand.
Injectable dermal fillers continue to increase in popularity in aesthetic medicine. Although rare, vision loss secondary to filler injections is a devastating complication associated with a poor visual prognosis. The mechanism for vision loss is thought to be related to retrograde embolization of the dermal filler from peripheral vessels in the face into the ophthalmic arterial system.
View Article and Find Full Text PDFHyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations.
JMIR Dermatol
January 2024
Ailesbury Clinics Ltd, Dublin, Ireland.
Background: Hyaluronidase (Hyal) can reverse complications of hyaluronic acid (HA) fillers, which has contributed substantially to the popularity of such procedures. Still, there are differing opinions regarding Hyal treatment, including dosage recommendations in filler complication management.
Objective: We aimed to address unanswered questions regarding Hyal treatment for HA filler complications, including timing and dosage, skin pretesting, properties of various Hyals and interactions with HA gels, and pitfalls of the treatment.
[Effectiveness and interest of retrobulbar hyaluronidase injections in the treatment of blindness complicating facial hyaluronic acid injections: A literature review].
Ann Chir Plast Esthet
January 2024
Service de chirurgie maxillo-faciale et stomatologie, CHU-Hôpitaux de Rouen, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen cedex, France; Laboratoire d'anatomie, UFR Santé de Rouen, université de Rouen-Normandie, 22, boulevard Gambetta, 76000 Rouen, France; CETAPS, EA3832, Research Center for Sports and Athletic Activities Transformations, University of Rouen Normandy, Mont-Saint-Aignan, France.
Introduction: Hyaluronic acid injections are becoming increasingly common among both the general public and the medical community, but they are not without risks. The occurrence of blindness, although rare, is a tragic event for both the patient and the practitioner. One of the treatments proposed in the literature is to inject hyaluronidase as close as possible to the site of ischemia, retrobulbarly.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!